Literature DB >> 9390772

GLUT-1 expression in the cerebra of patients with Alzheimer's disease.

A D Mooradian1, H C Chung, G N Shah.   

Abstract

To investigate the molecular basis of reduced GLUT-1 concentration of the blood-brain barrier in patients with Alzheimer's disease (AD), the GLUT-1 mass, mRNA content, and structure were studied in eight patients with AD and seven age-matched controls. The results indicate that the 55-kDa GLUT-1 is significantly reduced in AD without a significant change in GLUT-1 mRNA concentrations. Because in some animal models changes in GLUT-1 expression is associated with changes in GLUT-1 mRNA structure, the length of the poly(A) tail of the GLUT-1 mRNA was estimated with a reverse transcription-polymerase chain reaction technique. The length of poly(A) tail of GLUT-1 mRNA in AD subjects was not significantly different from the controls. It is concluded that the AD-related change in GLUT-1 expression is not the result of altered poly(A) length of GLUT-1 mRNA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390772     DOI: 10.1016/s0197-4580(97)00111-5

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  60 in total

Review 1.  Metabolic reserve as a determinant of cognitive aging.

Authors:  Alexis M Stranahan; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 3.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

Review 4.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 5.  The effect of aging on brain barriers and the consequences for Alzheimer's disease development.

Authors:  Nina Gorlé; Caroline Van Cauwenberghe; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mamm Genome       Date:  2016-05-03       Impact factor: 2.957

Review 6.  Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.

Authors:  Abhay P Sagare; Robert D Bell; Berislav V Zlokovic
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

7.  Sugar and Alzheimer's disease: a bittersweet truth.

Authors:  Costantino Iadecola
Journal:  Nat Neurosci       Date:  2015-04       Impact factor: 24.884

Review 8.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 9.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

10.  Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease.

Authors:  Ying Liu; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  FEBS Lett       Date:  2008-01-02       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.